Here I briefly discuss a challenging case of a patient who has an exon 20 mutation in the EGFR gene, which isn't one of the mutation types associated with a high probability of responding well to an oral EGFR inhibitor.  I cover the approach I favored and also some limited information that has just emerged to help clarify what we might expect for patients with an uncommon to rare variant  of an EGFR mutation (~5% of mutations detected).

[powerpress]

I hope it's interesting and helpful.  As always, I welcome your comments and questions.